United Therapeutics Corporation (UTHR)
United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom
Despite legal challenges and exclusivity risks, United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. UTHR is innovating in organ transplantation and bioengineered organs, including xenotransplantation and ex vivo lung perfusion, which could revolutionize the market. Legal battles, particularly with Liquidia, threaten United Therapeutics' intellectual property, affecting its Tyvaso franchise and competitive position in PAH.
United Therapeutics: One To Believe In Despite Competitive Threats
United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has maintained resilience, leveraging strategic litigation and innovative product development to protect and grow its revenue streams. United's future growth hinges on expanding Tyvaso DPI's market and advancing its pipeline, including promising IPF treatments and groundbreaking organ transplant technologies.
United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics Q3 Earnings & Sales Beat Estimates
UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.
United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Andreas Argyrides - Oppenheimer Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Operator Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2024 Earnings Webcast. My name is Dave, and I will be your conference operator today.
Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates
United Therapeutics (UTHR) came out with quarterly earnings of $6.39 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $5.38 per share a year ago.
Curious about United Therapeutics (UTHR) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for United Therapeutics (UTHR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
United Therapeutics (UTHR) Up 9.9% Since Last Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics Shares Thrive
Revenue growth and a recent regulatory win are driving shares of United Therapeutics Corporation (UTHR) upward.
United Therapeutics: Economics Support Compounding Ability
United Therapeutics Corporation remains a buy with strong growth potential and high returns on invested capital. Q2 FY'24 earnings show continued growth in sales and earnings, with upsides in its Tyvaso segment. The company has started share buybacks and is on track to reach a $3 billion revenue run rate by FY'25, supporting a valuation of $400/share.
